[1] Romero N B, Clarke N F. Congenital myopathies [J]. Handb Clin Neurol, 2013, 113:1321-1336.
[2] Snoeck M,van Engelen B G,Küsters B, et al. RYR1-related myopathies: a wide spectrum of phenotypes throughout life [J]. Eur J Neurol. 2015, 22(7): 1094-1112.
[3] Ferreira A F, Carvalho M S, Resende M B, et al. Phenotypic and immunohistochemical characterization of sarcoglycanopathies [J]. Clinics (Sao Paulo), 2011, 66(10): 1713-1719.
[4] Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy [J]. J Med Genet, 2016, 53(3):145-151.
[5] Cagliani R 1, Fruguglietti M E, Berardinelli A, et al. New molecular findings in congenital myopathies due to selenoprotein N gene mutations [J]. J Neurol Sci, 2011, 300(1-2): 107-113.
[6] Schara U, Kress W, Bönnemann C G, et al. The phenotype and long-term follow-up in 11 patients with juvenile selenoprotein N1-related myopathy [J]. Eur J Paediatr Neurol, 2008,12(3): 224-230.
[7] Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies [J]. Am J Hum Genet, 2002, 71(4): 739-749.
[8] Belaya K, Rodríguez Cruz P M, Liu W W, et al. Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies [J]. Brain, 2015, 138(Pt 9): 2493-2504.
[9] Oestergaard S T, Stojkovic T, Dahlqvist J R, et al. Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T) [J]. Neurol Genet, 2016,2(6):e112.
[10] Van den Bergen J C, Hiller M, Böhringer S, et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants [J]. J Neurol Neurosurg Psychiatry, 2015, 86(10): 1060-1065.
[11] Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes [J]. Auto Immun Highlights,2014,5(3):69-75.
[12] Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management [J]. CIurr Rheumatol Rep, 2015, 17(12): 72.
[13] Pinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments [J]. Curr Opin Rheumatol, 2016, 28(6):619-624.
[14] Filli L, Winklhofer S, Andreisek G, et al. Imaging of myopathies [J]. Radiol Clin North Am, 2017, 55(5): 1055-1070.
[15] Mendell J R, Rodino-Klapac L R, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy [J]. Ann Neurol, 2013, 74(5): 637-647.
[16] Kesselheim A S, Avorn J. Approving a problematic muscular dystrophy drug: implications for FDA policy [J]. JAMA, 2016, 316(22): 2357-2358.
[17] Mendell J R, Goemans N, Lowes L P, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy [J]. Ann Neurol, 2016, 79(2):257-271.
[18] McDonald C M, Campbell C, Torricelli R E, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2017, 6736(17): 31611-31612.
[19] Long C, Amoasii L, Bassel-Duby R, et al. Genome editing of monogenic neuromuscular diseases: a systematic review [J]. JAMA Neurol, 2016, 73(11): 1349-1355.
[20] Glascock J, Lenz M, Hobby K, et al. Cure SMA and our patient community celebrate the first approved drug for SMA [J]. Gene Ther, 2017,24(9):498-500.
[21] Nelson S F, Miceli M C. FDA approval of Eteplirsen for muscular dystrophy [J]. JAMA, 2017, 317(14):1480.
[22] Hehir M K, Hobson-Webb L D, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review [J]. Neurology, 2017, 89(10):1069-1077.
[23] Aggarwal R, Bandos A, Reed A M, et al. Predictors of clinical improvement in Rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis[J]. Arthritis Rheumatol, 2014,66(3): 740-749.